Condition (MeSH)
Cysticercosis
ClinicalTrials.gov lists 26 trials for Cysticercosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 26 trials are tagged with Cysticercosis itself; the rest are tagged with a narrower condition beneath it.
When did Cysticercosis trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2016 | 3 |
| 2015 | 1 |
| 2014 | 3 |
| 2012 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 26 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cysticercosis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2/3 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 8 |
How many Cysticercosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 1 |
| Completed | 17 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cysticercosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| National Institute of Mental Health (NIMH) | 2 |
| Cephas Health Research Initiative Inc, Ibadan, Nigeria | 1 |
Which drugs are being tested for Cysticercosis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Albendazole | 5 |
| Oxfendazole | 2 |
| Omeprazole 20 mg | 1 |
| Phenytoin | 1 |
| Praziquantel | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone/Dexamethasone acetate | 3 |
| Albendazole and praziquantel | 2 |
| 28 days of albendazole 15 mg/kg/day | 1 |
| Oxfendazole three doses | 1 |
| Oxfendazole single dose | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cysticercosis trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Prolonged hospitalization | 4 | 1 |
Which publications cover Cysticercosis? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Knowledge, attitudes and practices related to Taenia solium cysticercosis and taeniasis in Tanzania. | BMC infectious diseases | 2022 | Yes |
| Taenia solium cysticercosis and taeniosis: Achievements from the past 10 years and the way forward. | PLoS neglected tropical diseases | 2017 | Yes |
| Taenia solium taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa. | Parasites & vectors | 2015 | Yes |
| Prevalence of and Factors Associated with Human Cysticercosis in 60 Villages in Three Provinces of Burkina Faso. | PLoS neglected tropical diseases | 2015 | Yes |
| Persistent MR contrast enhancement of calcified neurocysticercosis lesions. | AJNR. American journal of neuroradiology | 1998 | Yes |
Showing 5 of 19 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cysticercosis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Cysticercosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Cysticercosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Cysticercosis | 1560 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Cysticercosis | 1560 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.